Abstract
Osteoarthritis is the most common form of arthritis and causes substantial morbidity and healthcare expenditure worldwide. This is partly due to the gastrointestinal side effects associated with the use of nonspecific nonsteroidal anti-inflammatory drugs. Cyclooxygenase-2 specific inhibitors offer a therapeutic alternative since they may reduce gastrointestinal-related risks with a similar clinical efficacy to nonsteroidal anti-inflammatory drugs. This article provides an overview of the clinical and economic value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis. The authors’ findings suggest that cyclooxygenase-2 specific inhibitors show comparable efficacy with nonspecific nonsteroidal anti-inflammatory drugs, yet have reduced rates of gastrointestinal complications. Pharmacoeconomic studies have demonstrated the cost-effectiveness of prescribing cyclooxygenase-2 specific inhibitors in certain high-risk populations. Cyclooxygenase-2 specific inhibitors provide clinical and economic benefits in patients diagnosed with osteoarthritis. Future studies should further examine the economic implications of newer cyclooxygenase-2 inhibitors and quantify the impact of pain management on patients’ quality of life.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Expert Review of Pharmacoeconomics & Outcomes Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
